Sugi Predict

Sugi Predict / Compounds / SCHEMBL4115264

SCHEMBL4115264

SCHEMBL4115264

CC1(O)CC[C@H]2[C@@H]3CCC4CC(=O)C=C[C@]4(C)[C@@H]3CC[C@@]21C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHBG P04278 6/20 0.55
▸ MAPK1 P28482 2/20 0.55
▸ POLB P06746 1/20 0.55
▸ AR P10275 1/20 0.53
▸ ALDH1A1 P00352 4/20 0.50
▸ LMNA P02545 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ NR3C1 P04150 2/20 0.50
▸ PGR P06401 2/20 0.50
▸ ADORA3 P0DMS8 2/20 0.50
▸ ABCB11 O95342 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ AGTR1 P30556 1/20 0.50
▸ PTGS2 P35354 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ GUSB P08236 1/20 0.49
▸ ADRA1A P35348 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28827028 1.00 SHBG (0.55) SHBGMAPK1POLBARALDH1A1
SCHEMBL28060038 1.00 SHBG (0.55) SHBGMAPK1POLBARALDH1A1
SCHEMBL4115261 1.00 SHBG (0.55) SHBGMAPK1POLBARALDH1A1
SCHEMBL13855720 1.00 SHBG (0.55) SHBGMAPK1POLBARALDH1A1
SCHEMBL13558383 0.85 SERPINA6 (0.52) SHBGMAPK1POLBARALDH1A1
SCHEMBL5700376 0.85 AR (0.41) SHBGMAPK1POLBARALDH1A1
SCHEMBL11336320 0.85 STS (0.44) SHBGMAPK1POLBARALDH1A1
SCHEMBL11036779 0.85 STS (0.44) SHBGMAPK1POLBARALDH1A1
SCHEMBL5700374 0.85 AR (0.41) SHBGMAPK1POLBARALDH1A1
SCHEMBL11036780 0.85 STS (0.44) SHBGMAPK1POLBARALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389501-B2 Anticancer compound Saifullah (PK) 2013-03-05 — — US claimed
US-20130018025-A1 Anticancer Compound HEJ RESEARCH INSTITUTE OF CHEMISTRY (PK) 2013-01-17 — — US claimed
US-8329678-B1 Antiinflammatory compound ULLAH SAIF (PK) 2012-12-11 — — US claimed
US-7009063-B2 Process for the production of oxandrolone BARR LABORATORIES, INC. (US) 2006-03-07 — — US claimed
US-20050004376-A1 Process for the production of oxandrolone BARR LABORATORIES, INC. 2005-01-06 — — US claimed
US-6787659-B2 OXIDATION OF MESTANOLONE; HYDROXYLATION; REDUCTION BARR LABORATORIES, INC. 2004-09-07 — — US claimed
WO-2004064722-A2 PROCESS FOR THE PRODUCTION OF OXANDROLONE ENDEAVOR PHARMACEUTICALS, INCORPORATED (US) 2004-08-05 — — WO claimed
US-20030109721-A1 Process for the production of oxandrolone BARR LABORATORIES, INC. 2003-06-12 — — US claimed
US-20210346385-A1 TASTE-MASKED DOSAGE FORMS DEEP OCEAN CAPITAL MANAGEMENT LP 2021-11-11 — — US disclosed
EP-3172566-B1 SAMPLE ANALYSING DEVICE INTELLIGENT FINGERPRINTING LTD (GB) 2019-10-16 — — EP disclosed
US-20170307605-A1 SAMPLE ANALYSING DEVICE INTELLIGENT FINGERPRINTING LIMITED (GB) 2017-10-26 — — US disclosed
EP-3172566-A1 SAMPLE ANALYSING DEVICE Intelligent Fingerprinting Limited (GB) 2017-05-31 — — EP disclosed
WO-2016012812-A1 SAMPLE ANALYSING DEVICE INTELLIGENT FINGERPRINTING LIMITED (GB) 2016-01-28 — — WO disclosed
US-8455264-B2 Fluorescence based detection of substances INTELLIGENT FINGERPRINTING LIMITED (GB) 2013-06-04 — — US disclosed
WO-2002100881-A1 PROCESS FOR THE SYNTHESIS OF OXANDROLONE CEDARBURG PHARMACEUTICALS, LLC (US) 2002-12-19 — — WO disclosed
US-6448413-B1 17-HYDROXY-17-METHYL-1,3-SECO-2-NOR-5-ANDROSTANE-3-ACID DERIVATIVES FROM MESTANOLONE AND AROMATIC NITRO-ALDEHYDE RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2002-09-10 — — US disclosed
EP-1189885-A1 PROCESS FOR THE SYNTHESIS OF A-NOR-SECO COMPOUNDS WITH STERANE SKELETON RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2002-03-27 — — EP disclosed
EP-1189925-A1 NEW PROCESS FOR THE SYNTHESIS OF 17BETA-HYDROXY-17ALPHA-METHYL-2-OXA-5ALPHA-ANDROSTANE-3-ONE RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2002-03-27 — — EP disclosed
WO-2000076968-A1 PROCESS FOR THE SYNTHESIS OF A-NOR-SECO COMPOUNDS WITH STERANE SKELETON Richter Gedeon Vegyészeti Gyár Rt. (HU) 2000-12-21 — — WO disclosed
WO-2000077025-A1 NEW PROCESS FOR THE SYNTHESIS OF 17β-HYDROXY-17α-METHYL-2-OXA-5α-ANDROSTANE-3-ONE Richter Gedeon Vegyészeti Gyár Rt. (HU) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004376-A1 Process for the production of oxandrolone CYP17A1, CYP21A2, SRD5A1 SHBG 89/4885MAPK1 798/4885POLB 1285/4885
US-20030109721-A1 Process for the production of oxandrolone CYP17A1, CYP21A2, SRD5A1 SHBG 101/4885MAPK1 913/4885POLB 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.